![Robert de Jonge](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Robert de Jonge
Nessuna posizione attualmente
Profilo
Robert de Jonge worked as the Chief Risk Officer at reMYND NV.
He graduated from the University of Leiden and Delft University of Technology with graduate degrees.
Precedenti posizioni note di Robert de Jonge
Società | Posizione | Fine |
---|---|---|
reMYND NV
![]() reMYND NV Miscellaneous Commercial ServicesCommercial Services reMYND NV engages in the development of disease-modifying treatments against alzheimer's, parkinson's, diabetes and other protein misfolding disorders. Its drug and development unit focuses on innovative, disease-modifying drugs for treating degenerative disorders. The company was founded by Fred Van Leuven, Stefaan Wera and Joris Winderickx in 2002 and is headquartered in Leuven, Belgium. | Corporate Officer/Principal | - |
Formazione di Robert de Jonge
Delft University of Technology | Graduate Degree |
University of Leiden | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 1 |
---|---|
reMYND NV
![]() reMYND NV Miscellaneous Commercial ServicesCommercial Services reMYND NV engages in the development of disease-modifying treatments against alzheimer's, parkinson's, diabetes and other protein misfolding disorders. Its drug and development unit focuses on innovative, disease-modifying drugs for treating degenerative disorders. The company was founded by Fred Van Leuven, Stefaan Wera and Joris Winderickx in 2002 and is headquartered in Leuven, Belgium. | Commercial Services |
- Borsa valori
- Insiders
- Robert de Jonge